# Abiraterone With Different Steroid Regimens for Side Effect Related to Mineralcorticoid Excess Prevention in Prostate Cancer Prior to Chemotherapy

> **NCT01867710** · PHASE2 · COMPLETED · sponsor: **Janssen Pharmaceutica N.V., Belgium** · enrollment: 164 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Abiraterone Acetate
- **DRUG:** Prednisone 5 mg twice daily
- **DRUG:** Prednisone 5 mg once daily
- **DRUG:** Prednisone 2.5 mg twice daily
- **DRUG:** Dexamethasone 0.5 mg once daily

## Key facts

- **NCT ID:** NCT01867710
- **Lead sponsor:** Janssen Pharmaceutica N.V., Belgium
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07-16
- **Primary completion:** 2015-04-20
- **Final completion:** 2018-06-05
- **Target enrollment:** 164 (ACTUAL)
- **Last updated:** 2019-07-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01867710

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01867710, "Abiraterone With Different Steroid Regimens for Side Effect Related to Mineralcorticoid Excess Prevention in Prostate Cancer Prior to Chemotherapy". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01867710. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*